# A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy

> **NCT07662200** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Ottawa Hospital Research Institute** · enrollment: 10 (estimated)

## Conditions studied

- Germ Cell Cancer

## Interventions

- **DRUG:** Netupitant/Palonosetron Hydrochloride
- **DRUG:** Ondansetron (Control)
- **DRUG:** Aprepitant
- **DRUG:** Dexamethasone
- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT07662200
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662200, "A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*